AZN - Astrazeneca PLC Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 SPY (-2.57%) TVIX (23.27%) VXX (12.47%) SPLK (0.13%) SPX (-2.57%) TQQQ (-9.16%) ZS (-1.74%) TGEN (1.52%) SYNH (-2.58%) SUPV (-4.31%) SPOT (-2.08%) QQQ (-3.17%) PNC (%) PINS (%) PFE (-2.11%) PANW (-1.47%) NVDA (-5.28%) MELI (-3.43%) MCD (-2.21%) IWM (-3.07%) HQY (-3.52%) GSK (0.52%) GLD (1.96%) EW (%) CMI (-3.18%)

AZN - Astrazeneca PLC

$44.58 -0.83[-1.83%]

15 mins delayed data

People also watch : LLY | BIIB | JNJ | SNY | BMY | PFE

+Watchlist

4 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$45.41	Open	$45.28
Volume	3.76M	Market Cap	98.408B
Yield		Last Dividend

Day

52 Week

Bulls And Bears Of The Week: Chevron, Di...	12:04 PM
Benzinga has examined the prospects for many investor favorite stocks over the past week. It was another tough week for the markets, with the Dow Jon...

10 Biopharmaceutical Companies Trying To...	10:46 AM
Cancer. Research shows nearly every sixth death in the world is due to the disease, making it the second leading cause of death behind cardiovascular ...

We Think AstraZeneca (LON:AZN) Can Stay ...	1:55 AM
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Pharma Stock Roundup: ABBV's Rinvoq ...	08/23/19
FDA approves AbbVie's (ABBV) upadacitinib to be marketed as Rinvoq. Bayer (BAYRY) is set to divest its Animal Health unit to Elanco for $7.6 billi...

Roche's Tecentriq Gets Japan's N...	08/23/19
Roche (RHHBY) gets approval for Tecentriq in Japan for extensive-stage SCLC.

AstraZeneca's Kidney Drug Roxadustat...	08/22/19
AstraZeneca's (AZN) roxadustat gets a second marketing approval in China for treating anaemia caused by chronic kidney disease in non-dialysis-dep...

The Daily Biotech Pulse: ViiV's Long-Act...	08/22/19
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 21) ...

AstraZeneca's Imfinzi Fails in Stage...	08/21/19
AstraZeneca's (AZN) Imfinzi fails to improve overall survival in a study for previously treated stage IV non-small cell lung cancer (NSCLC) patien...

AstraZeneca's Drug Combo To Treat Non-Sm...	08/21/19
AstraZeneca plc (NYSE: AZN ) faced a clinical setback in a study evaluating a combo drug regimen in non-small cell lung cancer, or NSCLC. What Happene...

UPDATE 2-AstraZeneca Imfinzi combination...	08/21/19
A combination of AstraZeneca's lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small c...

AstraZeneca faces setback in lung cancer...	08/20/19
AstraZeneca has disclosed a setback for one of its key cancer treatments, saying a trial involving immunotherapy drug Imfinzi was no more effective th...

ANALYST RATINGS

1 analyst ratings (Last 6 months)

100.00 %

Strong Buy + Buy

Price Target (PT)

Strong Buy rating	04/01/19
Cowen & Co. upgrades from Market Perform to Outperform rating and raises Price Target from $42.00 to $48.00

EARNINGS

Date	04/12/2019 (AMC)	Est. (EPS/Rev.)	$1.37
Actual (EPS/Rev.)	$2.5B	EPS (TTM)	$???

TRADERS TRACKING $AZN

Service Name	Trader	% Success
Alpha Swing Trades	Jonathan	69.00 %	Follow
LavaPit	Steve Pitkin	58.00 %	Follow
Best Trading Ideas	Best Trading Ideas	53.00 %	Follow

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Follow Us

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.